Table of Contents- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commissi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4670809 (State or other jurisdiction of incorporation) (IRS Employer Identificat ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2019 Earnings Conference Call March 5, 2020 4:30 PM ET Company Participants Zack Kubow - Investor Relations, Pure Communications Richard Miller - President and Chief Executive Officer Leiv Lea - Chief Financial Officer Conference Call Participants Tony Butler - ROTH Capital Partners Mara Goldstein - Mizuho Jeet Mukherjee - Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by and welcome to the Corvus Pharmaceuticals Fourth Quarter 2 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commi ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2019 Results Conference Call October 29, 2019 4:30 PM ET Company Participants Zack Kubow - IR, Pure Communications Richard Miller - CEO Leiv Lea - CFO Dr. Stephen Willingham - Senior Scientist Conference Call Participants Biren Amin - Jefferies Tony Butler - ROTH Capital Partners Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2019 Update and Financial Results Webcast. Today's conf ...

Corvus Corporate Presentation Wedbush Healthcare Conference Aug 14, 2019 Forward-Looking Statements / Safe Harbor 2 This presentation and the accompanying oral presentation contain "forward‐looking" statements, including statements related to the potential safety and efficacy of CPI-006, ciforadenant and CPI-818, the potential similarities of BTK inhibition and ITK inhibition, the Company's ability to develop and advance product candidates into and successfully complete preclinical studies and clinical tria ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2019 Earnings Conference Call August 1, 2019 4:30 PM ET Company Participants Zack Kubow - IR, Pure Communications Leiv Lea - CFO Richard Miller - President & CEO Conference Call Participants Michael Morabito - Crédit Suisse Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Second Quarter 2019 Business Update and Financial Results Conference Call. As a reminder, today's conference is being recorded ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commission ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Zack Kubow - IR, Pure Communications Leiv Lea - CFO Richard Miller - President & CEO Conference Call Participants Biren Amin - Jefferies Michael Vincent Morabito - Crédit Suisse Robert Driscoll - Wedbush Securities Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals First Quarter 2019 Business Update and Financial Results Conf ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commissio ...